Becton Dickinson And 

CHF245.48
728
+CHF0+0% Tuesday 14:30

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
45.7
股息殖利率
-
股息
-

即將到來

股息

0%股息殖利率
Mar 25
CHF0.85
Dec 24
CHF0.85
Sep 24
CHF0.85
Jun 24
CHF0.85
Mar 24
CHF0.85
10年成長
6.08%
5年成長
3.02%
3年成長
4.85%
1年成長
1.64%

財報

30Apr預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
2.21
2.79
3.38
3.96
預期EPS
2.775
實際EPS
不適用

財務

9.08%利潤率
有盈利
2017
2018
2019
2020
2021
2022
18.32B營收
1.66B淨利

分析師評級

$194.25平均目標價
最高預估為 221.29。
來自過去6個月內的 11 則評分。這不是投資建議。
買入
55%
持有
45%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 BDX.SW 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Show more...
執行長
Mr. Thomas E. Polen Jr.
員工
77000
國家
United States
ISIN
US0758871091
WKN
000857675

上市

0 Comments

分享你的想法

FAQ

Becton Dickinson And 今天的股價是多少?
BDX.SW 目前價格為 CHF245.48 CHF,過去 24 小時上漲了 +0%。在圖表上更密切關注 Becton Dickinson And 股價表現。
Becton Dickinson And 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Becton Dickinson And 的股票以代號 BDX.SW 進行交易。
Becton Dickinson And 去年的營收是多少?
Becton Dickinson And 去年的營收為 18.32BCHF。
Becton Dickinson And 去年的淨利是多少?
BDX.SW 去年的淨收益為 1.66BCHF。
Becton Dickinson And 會發放股息嗎?
是的,BDX.SW 的股息每 每季 發放一次。每股最新股息為 0.85 CHF。截至今日,股息殖利率(FWD)% 為 0%。
Becton Dickinson And 有多少名員工?
截至 April 01, 2026,公司共有 77,000 名員工。
Becton Dickinson And 位於哪個產業?
Becton Dickinson And從事於Healthcare產業。
Becton Dickinson And 何時完成拆股?
Becton Dickinson And 最近沒有進行任何拆股。
Becton Dickinson And 的總部在哪裡?
Becton Dickinson And 的總部位於 United States 的 Franklin Lakes。